Argentine triple therapy for cystic fibrosis shows efficacy in children aged 2+

New evidence published in scientific journals supports the efficacy of an Argentine triple therapy for cystic fibrosis in children, with ANMAT authorizing its use from age 2. Treatment improved lung function by 20.8% and secretion clearance by 13%. This expands therapeutic options for young patients, though long-term outcomes remain to be assessed.